Pliant Therapeutics Inc - Asset Resilience Ratio
Pliant Therapeutics Inc (PLRX) has an Asset Resilience Ratio of 53.53% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PLRX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Pliant Therapeutics Inc's Asset Resilience Ratio has changed over time. See PLRX net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Pliant Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Pliant Therapeutics Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $148.06 Million | 53.53% |
| Total Liquid Assets | $148.06 Million | 53.53% |
Asset Resilience Insights
- Very High Liquidity: Pliant Therapeutics Inc maintains exceptional liquid asset reserves at 53.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pliant Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Pliant Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Pliant Therapeutics Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Pliant Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 71.68% | $284.54 Million | $396.95 Million | -12.48pp |
| 2023-12-31 | 84.16% | $431.01 Million | $512.15 Million | -0.70pp |
| 2022-12-31 | 84.85% | $297.50 Million | $350.61 Million | +17.53pp |
| 2021-12-31 | 67.32% | $148.93 Million | $221.22 Million | -9.15pp |
| 2020-12-31 | 76.48% | $226.01 Million | $295.53 Million | +62.23pp |
| 2019-12-31 | 14.25% | $16.97 Million | $119.06 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $66.53 Million | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral,… Read more